Stratistics MRC에 따르면 세계의 혈장 유도체 시장은 2025년에 567억 1,000만 달러를 차지하고, 2032년에는 1,155억 2,000만 달러에 이를 것으로 예측되며, 예측 기간 중 CAGR은 10.7%를 나타낼 것으로 전망됩니다.
혈액의 액체 성분인 인간 혈장은 혈장 유도체로 알려진 특수한 의약품의 원료입니다. 면역 결핍증, 혈우병, 길란 밸리 증후군과 같은 모든 신경 증상은 이러한 도움으로 치료를 받고 있습니다.
세계의 혈우병 연맹(WFH)에 따르면, 혈우병은 세계에서 약 1만명에 1명의 비율로 발병하고 있습니다.
노인 증가
혈장 유래 요법 수요 증가의 주요 요인은 인구의 고령화입니다. 세계의 6명 중 1명이 65세 이상이 된다고 합니다. 또한 감염증, 심혈관 질환, 자가면역 질환의 리스크는 노화와 함께 증가합니다.이러한 질환의 대부분은 알부민이나 면역글로불린 등의 혈장 단백질로 치료됩니다.
제조 및 가공에 걸리는 엄청난 비용
복잡하고 시간이 많이 걸리는 혈장 분획 프로세스로 인해 혈장 유래의 치료제의 제조는 매우 비용이 많이 듭니다., 엄격한 품질 관리 시험, 대규모 보관 인프라가 필요합니다.또한, 소량의 완성품을 만드는데 몇 리터의 혈장이 필요하기 때문에 총 제조 비용이 상승합니다.
면역글로불린과 혈장 치료에 대한 관심 증가
면역 결핍, 신경질환, 자가면역질환 증가로 인해 면역글로불린 정주요법(IVIG)과 면역글로불린 피하주요법(SCIG) 수요가 높아지고 있습니다. 업계의 추계에 의하면, IVIG 수요는 세계적으로 연률 8% 이상으로 증가하고 있어 시장에는 큰 성장의 전망이 태어나고 있습니다.
혈장 제공 부족 및 공급 제한
혈장의 세계 공급은 공여자의 참여에 크게 의존하고 있으며, 그 참여는 사회 경제적 요인, 규제 제한, 혈장 제공에 관한 일반 시민의 태도에 따라 달라집니다. Dell에 의존하는 국가에 혼란을 일으킬 수 있습니다. 또한 COVID-19의 유행은 현저한 헌혈 감소로 면역글로불린과 응고 인자의 부족으로 인해 혈장 수집의 취약성을 밝혔습니다.
COVID-19 팬데믹은 제조 지연, 혈장 채취 중단, 면역글로불린 수요 증가를 일으켰기 때문에 혈장 유도체 시장에 큰 영향을 주었습니다. 특히 미국과 유럽과 같은 중요한 시장에서는 락다운이나 사회적 거리를 두는 정책에 의해 혈장 제공이 감소 조금, 혈장 유래의 중요한 치료제가 부족한 결과가 되었습니다. 또한, 다른 혈장 유래 제품공급 체인도, COVID-19 환자에 대한 회복기 혈장 요법에 관한 연구의 폭발적인 증가에 기인한 업계의 일시적인 초점의 시프트에 의해 영향을 받았습니다.
예측 기간 동안 면역글로불린 분절이 최대가 될 것으로 예상
자가면역질환, 원발성 및 이차성 면역 결핍증, 길란 밸리 증후군 및 만성 염증성 탈수성 다발신경염(CIDP) 등의 신경질환의 치료에 폭넓게 응용되고 있기 때문에 예측 기간 동안 면역글로불린 분야가 최대 시장 점유율을 차지할 것으로 예상됩니다. 요점은 고령자 증가, 면역 결핍증의 유병률 증가, 혈장 유래의 치료법에 대한 지식 증가에 의해 견인되고 있습니다.또한, 정맥내 투여(IVIG) 및 피하 투여(SCIG)용의 면역글로불린 제제의 개량에 의해 환자의 편리성과 치료 규정 준수가 향상하고 있습니다.
예측 기간 동안 크로마토그래피 분야의 CAGR이 가장 높을 것으로 예상
예측 기간 동안 혈장 단백질 분리에서 탁월한 효율성, 순도, 정밀도를 바탕으로 크로마토그래피 부문이 가장 높은 성장률을 보일 것으로 예측됩니다. 장유래의 치료에 대한 수요가 높아져, 친화성 크로마토그래피나 이온 교환 크로마토그래피의 개량, 바이오 의약품 연구에 대한 투자 증가 등이, 크로마토그래피의 급속한 보급에 박차를 가하고 있습니다.
예측 기간 동안 북미가 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 이 시장은 신경질환, 혈우병, 면역질환의 이환율 상승과 혈장 유래의 치료법에 대한 의식 증가에 의해 성장하고 있습니다.
예측 기간 동안 아시아태평양이 가장 높은 CAGR을 나타낼 것으로 예측됩니다. 생물학적 제제 및 혈장 분획에 대한 정부 지원, 혈장 수집 프로그램 증가, 의료 인프라 개선 등이 중국, 인도, 일본과 같은 국가의 급속한 확장에 기여하고 있습니다.
According to Stratistics MRC, the Global Blood Plasma Derivatives Market is accounted for $56.71 billion in 2025 and is expected to reach $115.52 billion by 2032 growing at a CAGR of 10.7% during the forecast period. Human plasma, the liquid component of blood, is the source of specialized medicinal products known as blood plasma derivatives. Essential proteins like albumin, immunoglobulins, clotting factors, and alpha-1 antitrypsin are among these derivatives and are frequently used to treat a variety of illnesses. Immunodeficiencies, hemophilia, and neurological conditions like Guillain-Barre syndrome are all treated with their help. Fractionation, a technique used to isolate and purify particular proteins for medical applications, yields plasma derivatives.
According to the World Federation of Hemophilia (WFH), hemophilia affects approximately 1 in 10,000 people globally.
Increasing number of elderly people
A major factor in the rising demand for therapies derived from plasma is the aging population. The elderly are significant users of plasma derivatives because they are more susceptible to diseases like coagulation problems, chronic liver disease, and immunological deficiencies. Approximately 1.6 billion people, or one in six people worldwide, will be over 65 by 2050, according to UN estimates. Additionally, the risk of infections, cardiovascular conditions, and autoimmune diseases increases with age; many of these conditions are treated with plasma proteins such as albumin and immunoglobulins.
Exorbitant expenses for production and processing
The complicated and time-consuming plasma fractionation process makes the production of therapies derived from plasma extremely costly. Plasma collection and final product release can take seven to twelve months, which results in high operating costs. For plasma proteins to remain stable and effective, plasma fractionation necessitates specialized equipment, rigorous quality control testing, and a sizable storage infrastructure. Furthermore, the total cost of production is raised by the requirement for several liters of plasma to generate a small amount of the finished product. For instance, to make enough Intravenous Immunoglobulin (IVIG) to treat one patient for a year, about 130 plasma donations are needed.
Growing interest in immunoglobulin and plasma treatments
Intravenous immunoglobulins (IVIG) and subcutaneous immunoglobulins (SCIG) are in high demand due to the increasing incidence of immune deficiencies, neurological conditions, and autoimmune diseases. Long-term immunoglobulin therapy is necessary for conditions like Kawasaki disease, chronic inflammatory demyelinating polyneuropathy (CIDP), and primary immunodeficiency disorders (PIDD). Industry estimates indicate that the demand for IVIG has been rising globally at a rate of more than 8% per year, which has created significant growth prospects for the market. Moreover, prospects for the market are further enhanced by the extension of plasma-derived immunoglobulin treatment indications into conditions like sepsis, multiple sclerosis, and Alzheimer's disease.
Lack of plasma donations and limitations on supply
The worldwide supply of plasma is largely reliant on donor participation, which varies depending on socioeconomic factors, regulatory limitations, and public attitudes regarding plasma donation. Policy changes and donor compensation ethical discussions could cause disruptions for nations like the US that depend on compensated plasma donation models. Additionally, the COVID-19 pandemic brought to light the vulnerability of plasma collection, as notable drops in donations resulted in immunoglobulin and clotting factor shortages.
The COVID-19 pandemic had a major effect on the market for blood plasma derivatives because it caused delays in manufacturing, disruptions in plasma collection, and an increase in demand for immunoglobulins. Lockdowns and social distancing policies caused plasma donations to drop, particularly in important markets like the US and Europe, which resulted in a shortage of vital therapies derived from plasma. Furthermore, the supply chain for other plasma-derived products was also impacted by the brief shift in industry focus caused by the explosion in research on convalescent plasma therapy for COVID-19 patients.
The Immunoglobulin segment is expected to be the largest during the forecast period
The Immunoglobulin segment is expected to account for the largest market share during the forecast period, motivated by its extensive application in the treatment of autoimmune diseases, primary and secondary immunodeficiency's, and neurological disorders like Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy (CIDP). The demand for immunoglobulin products has been driven by the growing number of elderly people, the increasing prevalence of immunodeficiency diseases, and the growing knowledge of plasma-derived treatments. Furthermore, improvements in immunoglobulin formulations for intravenous (IVIG) and subcutaneous (SCIG) administration have enhanced patient convenience and treatment compliance.
The Chromatography segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the Chromatography segment is predicted to witness the highest growth rate, motivated by its exceptional efficiency, purity, and precision in plasma protein separation. Chromatography is becoming more and more popular for producing immunoglobulins, albumin, and coagulation factors because it provides superior yield and specificity compared to conventional techniques like cold ethanol fractionation. Its quick adoption is being fueled by the rising demand for high-purity plasma-derived treatments, improvements in affinity and ion-exchange chromatography, and rising investments in biopharmaceutical research. Moreover, the market growth of chromatography-based purification is further enhanced by regulatory bodies' preference for it because of its superior pathogen removal capabilities.
During the forecast period, the North America region is expected to hold the largest market share, driven by a robust presence of major market players, high plasma donation rates, and sophisticated healthcare infrastructure. Because of its well-established plasma donation facilities and advantageous reimbursement policies, the United States leads the region and contributes significantly to global plasma collection. The market is growing due to the rising incidence of neurological diseases, hemophilia, and immune disorders, as well as increased awareness of therapies derived from plasma. Additionally, North America's dominant market position is also a result of the FDA's strong regulatory support, continuous research into plasma fractionation technologies, and widespread use of immunoglobulin treatments.
Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, driven by the growing prevalence of immunodeficiency disorders, growing awareness of plasma-derived therapies, and rising healthcare costs. Government support for biologics and plasma fractionation, growing plasma collection programs, and better healthcare infrastructure are all contributing to the rapid expansion of nations like China, India, and Japan. The market is growing as a result of rising demand for coagulation factors and immunoglobulins, as well as investments in sophisticated purification technologies and growing pharmaceutical manufacturing capacities.
Key players in the market
Some of the key players in Blood Plasma Derivatives Market include Bayer AG, Fusion Health Care Pvt. Ltd., Grifols, S.A., Takeda Pharmaceutical Company, Sanofi, CSL Limited, LFB S.A., Baxter International Inc., Syntegon, Green Cross Corporation, Octapharma AG, Biotest AG, Kedrion Biopharma, Inc., SK Plasma Co., Ltd. and Intas Pharmaceuticals Ltd.
In February 2025, Sanofi and CD&R have signed the share purchase agreement for the sale of a 50% controlling stake in its consumer health business Opella to US private equity firm Clayton Dubilier & Rice (CD&R). The terms of the transaction remain unchanged from those previously announced and closing is expected in the second quarter of 2025 at the earliest.
In January 2025, Bayer announced that the company has signed a new exclusive distribution agreement with UK-based Ecospray to market a biological liquid nematicide sourced from garlic. The product presents a biological alternative to traditional synthetic chemical nematicides in vegetable and potato crops, and will be marketed in the European Union under the new name Velsinum(TM).
In June 2024, Takeda announced the signing of an option agreement with Ascentage Pharma to enter into an exclusive license agreement for olverembatinib, an oral, potentially best-in-class, third-generation BCR-ABL tyrosine kinase inhibitor (TKI), which is currently in development for chronic myeloid leukemia (CML) and other hematological cancers.